Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-3) | terminated | Phase 3 | 315 | GlaxoSmithKlineINDUSTRY | 26 | Jul 10, 2024 | clinicaltrials |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY |
| 7 |
| Jun 26, 2024 |
| clinicaltrials |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 8 | Jun 26, 2024 | clinicaltrials |
| NCT05573724 | Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 2 | Jun 18, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | completed | Phase 2 | 126 | ImmunityBio, Inc.INDUSTRY | 7 | May 29, 2024 | clinicaltrials |
| NCT02899299 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients(CheckMate743) | completed | Phase 3 | 605 | Bristol-Myers SquibbINDUSTRY | 21 | May 21, 2024 | clinicaltrials |
| NCT03001882 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate 592) | completed | Phase 2 | 230 | Bristol-Myers SquibbINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT06334458 | Epigenomic and Machine Learning Models to Predict Pancreatic Cancer(IMAGene) | unknown | N/A | 170 | European Institute of OncologyOTHER | 4 | Mar 28, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT06275204 | H. Pylori Screen-and-treat Study in a Population of Young Adults | recruiting | — | 6,800 | University of LatviaOTHER | 6 | Mar 5, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT03694522 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer(FIGHT) | completed | Phase 2 | 155 | Five Prime Therapeutics, Inc.INDUSTRY | 18 | Feb 28, 2024 | clinicaltrials |
| NCT05161312 | A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial(Oncovox) | completed | N/A | 150 | Babes-Bolyai UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT02771795 | A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | terminated | — | 538 | Samsung Bioepis Co., Ltd.INDUSTRY | 7 | Feb 2, 2024 | clinicaltrials |
| NCT06238583 | Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors | no longer available | — | — | BayerINDUSTRY | 11 | Feb 2, 2024 | clinicaltrials |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide(OCEAN) | terminated | Phase 3 | 495 | Oncopeptides ABINDUSTRY | 21 | Jan 30, 2024 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT00818623 | Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | completed | Phase 2 | 172 | Ferring PharmaceuticalsINDUSTRY | 7 | Nov 30, 2023 | clinicaltrials |
| NCT00819156 | Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer | completed | Phase 2 | 189 | Ferring PharmaceuticalsINDUSTRY | 8 | Nov 30, 2023 | clinicaltrials |
| NCT04358406 | Rhu-pGSN for Severe Covid-19 Pneumonia | completed | Phase 2 | 64 | BioAegis Therapeutics Inc.INDUSTRY | 2 | Nov 28, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT02178956 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer(BRIGHTER) | completed | Phase 3 | 714 | Sumitomo Pharma America, Inc.INDUSTRY | 22 | Nov 15, 2023 | clinicaltrials |
| NCT04721002 | Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)(MEDICI) | completed | — | 514 | AbbVieINDUSTRY | 22 | Oct 18, 2023 | clinicaltrials |
| NCT06079684 | Baker Cyst Dimensions and Intermittent Vacuum Therapy in Knee Osteoarthritis (BCIVT)(BCIVT) | completed | N/A | 65 | Balnear and Rehabilitation Sanatorium TechirghiolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | terminated | Phase 3 | 96 | Gilead SciencesINDUSTRY | 10 | Aug 14, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT02481830 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer(CheckMate331) | completed | Phase 3 | 569 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 27, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT01111461 | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression | completed | Phase 2 | 133 | Eisai Inc.INDUSTRY | 8 | Jun 22, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT01327885 | Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma | completed | Phase 3 | 452 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT05135104 | Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period(PALBO) | unknown | — | 650 | Asociatia Oncohelp - Centrul de Oncologie OncohelpOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | unknown | Phase 3 | 140 | AB ScienceINDUSTRY | 8 | May 6, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials